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Abstract: Characteristic clinical manifestations of AFD such as acroparesthesias, angiokeratoma, corneal opacity, hypo/ and anhidrosis, 
gastrointestinal symptoms, renal and cardiac dysfunctions can occur in male and female patients, although heterozygous females with 
AFD usually seem to be less severely affected. The most prominent CNS manifestations consist of cerebrovascular events such as tran-
sient ischaemic attacks (TIAs) and (recurrent) strokes. For the most part, CNS complications in AFD have been attributed to cerebral 
vasculopathy, including anatomical abnormalities.  
The natural history of Fabry patients includes transitory cerebral ischaemia and strokes, even in very young persons of both genders. The 
mechanism is partly due to vascular endothelial accumulation of Gb-3. White matter lesions (WML) on occur MRI. Both males and fe-
males can be safely treated with enzyme replacement; and thus screening for Fabry disease of young stroke populations should be con-
sidered. There are, however, no hard data of treatment effect on mortality and morbidity. Stroke in Anderson-Fabry disease study of 721 
patients with cryptogenic stroke, aged 18–55 years, showed a high prevalence of Fabry disease in this group: 5% (21/432) of men and 3% 
(7/289) of women. Combining results of both sexes showed that 4% of young patients with stroke of previously unknown cause had 
Fabry disease, corresponding to about 1-2% of the general population of young stroke patients. Cerebral micro- and macro-vasculopathy 
have been described in Fabry disease. Neuronal globotriaosylceramide accumulation in selective cortical and brain stem areas including 
the hippocampus has been reported by autopsy studies in FD, but clinical surrogates as well as the clinical relevance of these findings 
have not been investigated so far. Another Neurologic hallmark of Fabry disease (FD) includes small fiber neuropathy as well as cerebral 
micro- and macroangiopathy with premature stroke. Cranial MRI shows progressive white matter lesions (WML) at an early age, in-
creased signal intensity in the pulvinar, and tortuosity and dilatation of the larger vessels. Conventional MRI shows a progressive load of 
white matter lesions (WMLs) due to cerebral vasculopathy in the course of FD. Another study has been conducted to quantify brain struc-
tural changes in clinically affected male and female patients with FD. The peripheral neuropathy in Fabry disease manifests as neuro-
pathic pain, reduced cold and warm sensation and possibly gastrointestinal disturbances. Patients with Fabry disease begin having pain 
towards the end of the first decade of life or during puberty. Children as young as 6 years of age have complained of pain often associated 
with febrile illnesses with reduced heat and exercise tolerance. The patients describe the pain as burning that is often associated with deep 
ache or paresthesiae. Some patients also have joint pain. A high proportion of patients with Fabry disease is at increased risk of develop-
ing neuropsychiatric symptoms, such as depression and neuropsychological deficits. Due to both somatic and psychological impairment, 
health-related quality of life (QoL) is considerably reduced in patients with Fabry disease.  
Targeted screening for Fabry disease among young individuals with stroke seems to disclose unrecognized cases and may therefore very 
well be recommended as routine in the future. Furthermore, ischemic stroke is related to inflammation and arterial stiffness and no study 
had addressed this relationship in patients with AF disease and cerebrovascular disease, so this topic could represent a possible future re-
search line.  
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INTRODUCTION 
 Anderson-Fabry Disease (AFD) is a rare genetic X-linked dis-
order with deficient activity of the lysosomal enzyme alpha-
galactosidase A [1]. The resultant progressive and diffuse accumu-
lation of neutral glycosphingolipids, especially of globotriaosylce-
ramide (Gb3) in vascular endothelium, kidneys, heart, brain, skin, 
cornea and other tissues leads to multiorgan pathology. Characteris-
tic clinical manifestations of AFD such as acroparesthesias, angi-
okeratoma, corneal opacity, hypo/ and anhidrosis, gastrointestinal 
symptoms, renal and cardiac dysfunctions can occur in male and 
female patients, although heterozygous females with AFD usually 
seems to be less severely affected [2,3,4]. In the central nervous 
system (CNS), diffuse lipid storage occurs in the cerebral vascula-
ture and neurons. The most prominent CNS manifestations (Table 
1) consist of cerebrovascular events such as transient ischaemic 
attacks (TIAs) and (recurrent) strokes [5,6,7]. For the most part, 
CNS complications in AFD have been attributed to cerebral vascu-
lopathy, including anatomical abnormalities (e.g. small vessel oc-
clusive disease, and large vessel ectasia and tortuosity) [8,9], 
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Table 1. Neurological and Sensory Organ Complications of Fabry 
Disease (from Nervous System Manifestations of Fabry 
Disease: Data from FOS – the Fabry Outcome Survey, 
Chapter 23) 
Central nervous system  
• Ischaemic stroke 
• Haemorrhagic stroke 
• Epilepsy 
• Cognitive impairment 
• Behavioural problems 
Peripheral nervous system  
• Painful small fibre neuropathy 
• Autonomic dysfunction 
Sensory organs  
• Ear – hearing loss, vertigo, tinnitus 
• Eye – cornea verticillata, subcapsular cataract, retinal vascular 
tortuosity 
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impairment of endothelial function and dysregulation of cerebral 
blood flow [10,11] (Fig. 1). Gb3 storages within neurons [12,13], 
cerebrovascular risk factors [14,15] and genetic factors [16] might 
increase additionally the likelihood of developing cerebrovascular 
disease. Brain magnetic resonance imaging (MRI) results often 
altered in AFD patients. In detail, neuroradiological findings in-
clude periventricular white matter signal intensity abnormalities and 
single or multiple lacunar infarcts (alterations typical of small ves-
sel disease), large ischemic cerebral infarctions, and posterior 
thalamus involvement (the so-called pulvinar sign) [17,18]. 
STROKE IN ANDERSON-FABRY DISEASE  
 Stroke and transitory cerebral ischemia are two possible com-
plications of Anderson-Fabry disease and there complications are 
due to to vascular endothelial accumulation of Gb-3, so on this 
basis these neurological complication are a clinical expression of a 
brain vessel disease causing lacunar lesions or larger lesions or 
white matter lesions (WML) on MRI. The analyses of results from 
ongoing studies will add to the decision on whether or not to screen 
young stroke patients for Fabry disease. Finally, stroke prophylactic 
therapy should be used liberally in patients of both genders with 
verified Fabry disease. This includes primary prevention such as 
lifestyle counseling, targeting blood pressure, managing atrial fibril-
lation, diabetes mellitus, hyperlipidaemia, and ASA. 
 Stroke in young adults is etiologically diverse and may repre-
sent a diagnostic challenge remaining cryptogenic in one-fourth of 
cases. Limited information is available on the prevalence of Fabry's 
disease, a treatable multisystem inherited lysosomal storage disor-
der, and disability in young patients with cryptogenic stroke. The 
Canadian Fabry Stroke Screening Initiative (CFSSI) [19] is a pro-
spective multicenter cohort study of young adults (age 18-55) pre-
senting with an ischemic stroke, transient ischemic attack, or intrac-
erebral haemorrhage of unknown etiology to stroke centres across 
Canada. Diagnosis of Fabry's disease is made by direct DNA analy-
sis of blood samples for -galactosidase gene mutations or poly-
morphisms. Demographics, clinical information, and investigations, 
including brain Magnetic Resonance Imaging (MRI), are collected. 
Functional neurological assessment includes neurological examina-
tion, the National Institutes of Health (NIH) stroke scale, modified 
Rankin scale, and the Barthel index. A follow-up interview is con-
ducted by telephone or in person approximately six-months after 
the index stroke/transient ischemic attack/intracerebral haemor-
rhage to determine patient outcomes, quality of life, and patient use 
of medications. Prevalence of positive DNA mutation or single 
nucleotide polymorphism screens for Fabry's disease as a propor-
tion of total cryptogenic stroke. Secondary outcomes include inci-
dent risk of new or recurrent vascular event at six-months, dis-
charge disposition, disability at six-months as measured by the 
modified Rankin scale, mean time from symptoms onset to the 
definite etiological diagnosis, and length of hospital stay. This study 
constitutes the first initiative to determine the prevalence of a posi-
tive screen for Fabry's disease in young adults with stroke in Can-
ada. Moreover, the Canadian Fabry Stroke Screening Initiative will 
provide information on recurrent vascular events, disability at six-
months (modified Rankin scale), and disposition in this understud-
ied population. 
 A recent study conducted in 721 patients with cryptogenic 
stroke showed a high prevalence of Fabry disease in this group. In 
particular this study showed that 5% of male subjects with crypto-
genic stroke and 3% of women had AFD [20] (Table 2). 
 These findings make AFA another potential cause of crypto-
genic stroke such as cardiogenic embolism, atherosclerotic vascu-
lopathy, and nontraumatic cervico-cerebral arterial dissection 
[21,22,23]. 
 Another study showed that in young stroke patients with proven 
Fabry disease, WML load was clearly higher than in patients with 
other causes of cryptogenic stroke without evidence for Fabry dis-
ease [20].  
 Rolfs and co-workers also showed in strokes patients with AFD 
disease had more frequently posterior strokes (vertebrobasilar) than 
in the carotid circulation. 
 A very recent study conducted by Sarikaya et al. [24] aimed to 
evaluate the frequency of unrecognized FD in a cohort of stroke 
patients at a tertiary stroke center. Patients suffering from first cryp-
togenic ischaemic stroke or transient ischaemic attack (TIA) at the 
age of 18-55 years were screened for the presence of FD. Authors 
measured the serum activity of -galactosidase (-GAL) in all pa-
tients. In addition, sequencing of -GAL gene was performed in 
men with low enzyme activity and in all women. They have re-
cruited 150 patients. The -GAL activity was low in nine patients 
(6%; six men and three women). Genetic sequencing in six men 
with low enzyme activity and all 48 women detected no -GAL 
gene mutation. This study suggests that the yield of screening for 
FD in patients with first cryptogenic ischaemic stroke or TIA is 
very low. Further large-scale studies are needed to investigate the 
importance of FD amongst patients with recurrent cryptogenic 
strokes. Nevertheless, the cause of initial ischemic stroke in up to 
30% of young patients remains unclear. Some authors hypothesized 
that alpha-Gal A deficiency is a rare cause of initial early-onset 
 
 
 
 
 
 
 
 
 
Fig. (1). 
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Table 2. Cerebrovascular and common clinical features in young adult patients with cryptogenetic stroke with and without Fabry disease 
 Stroke, no fabry disease 
(n=693) 
                Stroke with Fabry disease 
Male(n=21)                           Female(n=7) 
Clinical features    
Age at presentation(years) 47.9(9.6) 38.4(13.0) 40.3(13.1) 
Age range(years) 18-55 20-55 18-51 
Hemiparesis 378/608(68.1%) 15/21(71.4%) 4/7(57.1%) 
Ataxia  68/595(11.4%) 10/21(47.6%) 5/7(71.4%) 
Dysarthria  106/584/18.3%) 12/21(57.1%) 5/7(71.4%) 
Nausea or dizziness 99/573(17.3%) 11/21(52.4%) 3/7(28.6%) 
Nystagmus  44/548(8.0%) 13/21(61.9%) 2/7(28.6%) 
Multiple carebrovascular events 45/552(8.1%) 10/21(47.6%) 2/7(28.6%) 
Vascular pathology    
Atheromatous basal vessels 78/519(15.0%) 5/21(23.8%) 1/7(14.3%) 
Hypertension 216/608(35.5%) 6/21(28.6%) 2/7(28.6%) 
Dolichoectatic vertebrobasilar vessels 33/488(6.8%) 8/21(38.1%) 4/7(57.1%) 
Obesity(body mass index>30) 188/589(31.9%) 3/21(14.3%) 2/7(28.6%) 
Daily smoking 154/571(26.9%) 4/21(19.04%) 1/7(14.3%) 
Brain imaging    
Periventricular white matter hyperintensities 71/485(14.6%) 11/21(52.4%) 3/7(42.9%) 
Middle cerebral artery infarction 369/575(64.1%) 6/21(28.6%) 3/7(42.9%) 
Posterior cerebral artery infarction 48/575(8.3%) 3/21(14.3%) 1/7(14.3%) 
haemorrhage 29/575(5.0%) 3/21(14.3%) 0/7(0%) 
Normal  59/575(10.3%) 3/21(14.3%) 0/7(0%) 
Non neuronal clinical and lab features    
Acroparaesthesia  17/612(2.8%) 7/21(33.3%) 4/7(57.1%) 
Pain episode 11/608(1.8%) 5/21(23.8%) 2/7(28.6%) 
Angiokeratoma 12/466(2.6%) 6/21(28.6%) 1/7(14.3%) 
Hypohidrosis  54/512(10.5%) 15/21(71.4%) 2/7(28.6%) 
Cardiac abnormalities 111/580(19.1%) 6/21(23.8%) 2/7(28.6%) 
Cornea verticillata 0/331(0%) 5/21(23.8%) 2/7(28.6%) 
Proteinuria  31/527(5.5%) 9/21(42.9%) 5/7(71.4%) 
Factor-V mutation(1691G-A) 0/693(0%) 0/21(0%) 0/7(0%) 
Data are mean(SD)of number(%). *P<0.05 
 
ischemic stroke in men. The Stroke Prevention in Young Men 
Study [25] enrolled about 550 men (15 to 49 years) with first 
ischemic stroke in the Baltimore-Washington area in 2004 to 2007. 
Frozen plasma samples were assayed for alpha-Gal A activity, and 
DNA from patients with consistently low plasma alpha-Gal A ac-
tivities were sequenced. The study sample consisted of 558 men 
(42% African-American; median age 44 years). Stroke was crypto-
genic in 154 men (40% African-American). In 10 patients with low 
plasma alpha-Gal A activities, DNA sequencing identified altera-
tions in the alpha-Gal A gene in 2 patients. The polymorphism, 
D313Y, which results in low plasma enzyme activity, but near 
normal levels of cellular activity was seen in one European-
American male. The Fabry disease-causing A143T mutation was 
seen in an African-American male with cryptogenic stroke (0.18% 
of all strokes: upper 95% CI=0.53%; 0.65% of cryptogenic strokes: 
upper 95% CI=1.92%). In this biracial population, unrecognized 
Fabry disease is a rare but treatable cause of initial ischemic stroke 
in young men (Tables 3,4). 
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 The prevalence of Fabry disease, as reported by the study by 
Rolfs and coworkers, in young patients with cryptogenic stroke was 
reported to be as high as 4.9% in men and 2.4% in women [20]. 
This finding, however, was not reproduced in a smaller, retrospec-
tive study [26]. White matter lesions and vertebrobasilar dolichoec-
tasia are commonly found in patients with Fabry disease [27], but 
literature data on the prevalence of Fabry disease in patients with 
these neuroimaging findings are nonexistent.  
 On this basis the aim of the Belgian Fabry Study (BeFaS) [28] 
was to prospectively assess the frequency of Fabry disease in young 
Belgian patients with neurologic hallmarks of this disease, namely, 
stroke, unexplained white matter lesions, and vertebrobasilar doli-
choectasia (Fig. 2). In this national, prospective, multicenter study, 
authors screened for Fabry disease in 1000 patients presenting with 
ischemic stroke, transient ischemic attack, or intracranial hemor-
rhage; unexplained white matter lesions; or vertebrobasilar doli-
choectasia. In male patients, they measured alpha-galactosidase A 
(alpha-GAL A) activity in dried blood spots. Female patients were 
screened for mutations by exonic DNA sequencing of the alpha-
GAL A gene. Alpha-GAL A activity was deficient in 19 men 
(3.5%), although all had normal alpha-GAL A gene sequences. 
Enzymatic deficiency was confirmed on repeat assessment in 2 
male patients (0.4%). Authors identified missense mutations in 8 
unrelated female patients (1.8%): Asp313Tyr (n=5), Ala143Thr 
(n=2), and Ser126Gly (n=1). The pathogenicity of the 2 former 
missense mutations is controversial. Ser126Gly is a novel mutation 
that can be linked to late-onset Fabry disease. Alpha-GAL A defi-
ciency may play a role in up to 1% of young patients presenting 
with cerebrovascular disease. These findings suggest that atypical 
variants of Fabry disease with late-onset cerebrovascular disease 
exist, although the clinical relevance is unclear in all cases. 
 A study [29] was undertaken to better understand the natural 
history of cerebrovascular manifestations of Fabry disease. Data 
from 2446 patients in the Fabry Registry were analyzed to identify 
Table 3. Prevalence of Fabry disease in young men with cryptogenic ischemic stroke. 
                                      First Ischemic Stroke                                   Recurrent Ischemic Stroke 
 Total No. No. With Fabry Disease Prevalence Total No. No. With Fabry Disease Prevalence 
Rolfs* 367 8 2.17 41 10 24.3 
Brouns† 46 0 0 9 0 0 
Wozniak 154 1 0.65 N/A N/A  
*Estimated from reference 20using the following 4 assumptions: (1) total of 432 men with any stroke, assuming the same rate of hemorrhage as entire sample (5.5%), then 408 men 
with any ischemic stroke; (2) assuming the same rate of recurrent stroke as in the entire sample (10%), then 367 men had an initial ischemic stroke; (3) 10 men with Fabry disease 
had recurrent stroke and 11 with initial stroke; (4) given the high mortality rate of hemorrhage, assuming that 3 men with Fabry disease and hemorrhagic stroke were all initial 
strokes, then 8 men with Fabry disease had initial ischemic stroke †Dr R. Brouns and personal communication (Dr R. Brouns, 2009). 
 
Table 4. The Summary of Mutation Analysis in Patients with Consistently Low -Gal A Activity. 
-Gal A Activity†  
Initial Assay
‡
 Confirmatory Assay
‡
 Male Patients With Stroke Mutation Analysis 
  1 A143T 
  2 WT* 
  3 WT 
2.08 1.00 4 WT 
4.62 6.80 5 D313Y 
2.84 3.09 6 WT 
2.03 2.23 7 WT 
0.71 0.36 8 WT 
2.94 3.20 9 WT 
4.06 2.69 10 WT 
1.01 1.66   
3.04 1.67   
3.75 3.50   
*Wild type.  
†nmol/hr/mL protein; normal mean±SD: 15.6 nmol/hr/mL protein; normal mean=same for all patients. 
‡All values are means of duplicate enzyme assays 
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clinical characteristics of patients experiencing stroke during the 
natural history period (ie, before enzyme replacement therapy). A 
total of 138 patients [86 of 1243 males (6.9%) and 52 of 1203 fe-
males (4.3%)] experienced strokes. Median age at first stroke was 
39.0 years in males and 45.7 years in females. Most patients (70.9% 
of males and 76.9% of females) had not experienced renal or car-
diac events before their first stroke. Fifty percent of males and 
38.3% of females experienced their first stroke before being diag-
nosed with Fabry disease. Thirty patients (21 males and 9 females) 
had strokes at age <30 years. Most patients (86.8%) had ischemic 
strokes, but 16.9% of males and 6.9% of females had hemorrhagic 
strokes, among those for whom stroke type was reported. At the 
most recently available follow-up examination after their first 
stroke, 60% of males and 25.5% of females exhibited stage 3 to 5 
chronic kidney disease and 66.1% of males and 59.5% of females 
had left ventricular hypertrophy. All patients with Fabry disease, 
regardless of age or gender, should be monitored for possible cere-
brovascular complications, as stroke can occur in the absence of 
other key signs of the disease. 
 Cerebral micro- and macro-vasculopathy have been described 
in Fabry disease. Neuronal globotriaosylceramide accumulation in 
selective cortical and brain stem areas including the hippocampus 
has been reported by autopsy studies in FD, but clinical surrogates 
as well as the clinical relevance of these findings have not been 
investigated so far. Some authors [30] measured the hippocampus 
volumes in a group of clinically affected patients with FD and cor-
related the findings with the cognitive performance of the patients. 
Hippocampal volumes were determined manually on T1-weighted 
MR-images of 25 FD patients (age 36.5 ± 11.0 years) and 20 age-
matched controls. Additionally, individual white matter (WM) and 
gray matter (GM) volumes were measured using brain segmenta-
tion analyses. After controlling for age, white matter lesion (WML) 
volume, WM/GM-volumes and hippocampal volumes were signifi-
cantly decreased in FD. These findings were substantially more 
pronounced in a subgroup of men with FD. WM and WM/GM vol-
umes, and memory function did not significantly differ between 
patients and controls. In patients with FD hippocampal volumes 
were neither significantly correlated to WML volume nor to WM or 
WM/GM volumes. Hippocampus atrophy was not driven by the 
WML or other brain tissue atrophy and seems to correlate with the 
neuronal involvement in FD. In this young to middle-aged Fabry 
cohort the hippocampus degeneration was functionally compen-
sated without memory impairment. Longitudinal studies are needed 
to determine whether this degenerative component in FD will pro-
gress and, in concert with the individual WML-load, predict subse-
quent cognitive decline. 
CEREBRAL INVOLVEMENT IN ANDERSON-FABRY DIS-
EASE  
 White matter lesions (WML) and increased signal intensity in 
the pulvinar, and tortuosity and dilatation of the larger vessels (Fig. 
3) are typical neuroimaging findings of SNS involvement in Ander-
son-Fabry disease.  
 
 
 
 
 
 
 
 
 
 
 
Fig. (3). Schematic hypothesized mechanism of the development of WML 
in Fabry disease. WM: white matter. [From David F. Moore et al. White 
matter lesions in Fabry disease occur in ‘prior’ selectively hypometabolic 
and hyperperfused brain regions. Brain Research Bulletin Volume 62, Issue 
3, 30 December 2003] 
 
 
 
 
 
 
 
 
 
 
 
 
 
Fig. (2). Flowchart for the BeFaS. 
[Brouns R et al. Stroke 2010] 
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 Fellgiebel et al. [31] compared the diagnostic utility of the dif-
ferent MR imaging findings in patients with AFD. These authors 
evaluated MRI, MR angiography, and diffusion tensor imaging 
(DTI). Authors showed that 87% of the individuals were correctly 
classified by basilar artery diameters (sensitivity 95%, specificity 
83%) whereas WML volumes and global MD values did not sig-
nificantly separate patients from controls. On this basis, basilar 
artery diameters appair the most accurate neuroimaging finding to 
separate patients with Fabry disease (FD) from controls. Future 
studies should adopt basilar artery measurements for early detection 
and monitoring of brain involvement in FD. Moreover, further in-
vestigations should reveal if the dilated vasculopathy in FD could 
be a screening marker to detect FD in a cohort of other cerebrovas-
cular diseases, especially in cryptogenic stroke. 
 Cerebral manifestations that might be mainly due to progressive 
cerebrovascular dysfunction, are one major and often life-threa-
tening burden of the disease. In female FD patients who were con-
sidered to be less affected "carriers" for a long time, the prevalence 
of cerebrovascular events seems to be at last as high as in male 
patients. In structural imaging white matter lesions (WML) can be 
found frequently even in young FD patients. Clinically equally 
affected men and women with FD showed a comparable severity of 
WML load. Different pathophysiological aspects of cerebral an-
giopathy and WML development are discussed against the back-
ground of current concepts (e. g. accumulation of Gb3 in vascular 
endothelium with consecutive cell proliferation and luminal steno-
sis, acceleration of focal intravasal pressure and disturbances of 
vascular auto-regulation). Pathological increase of pulvinar signal 
in T1-weighted MRI has also been described in FD. This finding 
was assumed to be caused by calcification as a consequence of 
disturbed local circulation. To enhance our knowledge about the 
relevant neurobiological processes the authors propose a more sen-
sitive and early detection of brain structural changes in FD. New 
brain structural MRI methods such as diffusion-tensor imaging 
could provide a pattern of ultrastructural changes even in young 
patients without visible WML. This strategy could be as well useful 
for quantification of possible effects of the enzyme replacement 
therapy on brain structural alterations in FD. Based on recent data a 
systematic FD-screening by measuring Gb3 in urine of young pa-
tients with cryptogenic stroke should be discussed. Basically in 
such cases FD should be clinically considered. 
 Conventional MRI shows a progressive load of white matter 
lesions (WMLs) due to cerebral vasculopathy in the course of FD. 
Another study has been conducted [32] to quantify brain structural 
changes in clinically affected male and female patients with FD. 
Authors performed a prospective Diffusion-Tensor Imaging (DTI) 
study in 27 adult Fabry patients (13m, 14f) and 21 age-matched 
controls (12 m, 9f). Global Mean Diffusivity (MD) was increased in 
FD (P = 0.003) whereas global Fractional Anisotropy (FA) did not 
differ significantly between FD and controls. Even FD patients 
without significant WMLs (9m, 9f) showed increased global MD (P 
= 0.004). Regions of interest with significant MD elevations were 
located in the frontal, parietal and temporal white matter. No differ-
ences of thalamic and hippocampal DTI measurements could be 
detected between FD and controls. DTI parameters did not differ 
between male and female patients. The data provide the first evi-
dence of a pattern of marked structural brain tissue alterations in 
adult FD male and female patients even without WMLs. DTI seems 
to be an appropriate diagnostic tool to quantify brain tissue integrity 
in FD. Moreover, this method could be favorable for longitudinal 
assessment of brain structure alterations in FD, and for monitoring 
the cerebral effects of enzyme replacement therapy. 
 Conventional MRI shows an extensive load of white matter 
lesions (WMLs) which may already be present at an early stage in 
the disease. Albrecht et al. [33] investigator/ independent and sensi-
tive quantification of structural changes in the brain in clinically 
affected men and women with FD (Table 5). Authors performed a 
voxel based analysis of diffusion tensor images (DTI) in 25 patients 
with FD and 20 age matched normal controls. DTI revealed signifi-
cant increases in cerebral white matter mean diffusivity (MD) in 
patients with FD, which were pronounced in the periventricular 
white matter. Even the subgroup of patients without significant 
WMLs load (n = 18) showed increased diffusivity in the cerebral 
white matter. In gray matter areas, MD elevation was detected only 
in the posterior part of the thalamus, independent of the visible 
pulvinar alterations on T1 weighted images. Voxel based fractional 
anisotropy measurements did not differ significantly between pa-
tients and controls (Fig. 4). 
 The present study demonstrates the clinical feasibility of voxel 
based analysis of DTI as a sensitive tool to quantify brain tissue 
alterations in FD. The pattern of increased brain tissue diffusivity is 
probably due to microangiopathic alterations, mainly affecting the 
long perforating arteries. 
PERIPHERAL NERVE INVOLVEMENT IN AFD  
 The peripheral neuropathy is a typical and early clinical finding 
of Anderson-Fabry disease (Fig. 5). Although only up to 80% of 
Fabry patients develop neuropathic pain, they mostly will do so by 
age 20 years. Also female subjects may develop neuropathic pain 
[34,35].  
 The neuropathy of Fabry disease is associated with increased or 
immeasurable cold and warm detection thresholds in patients that 
are significantly different from controls in the hand, and foot[36]. 
Fabry patients also have reduced tolerance to a cold challenge [37].  
 The mechanism of AFD neuropathy is not well understood. 
Among possible causes a vasa nervorum glycolipid accumulation 
disease causing ischemia of nerves. Peripheral nervous system in-
volvement affect mainly small A delta and C fibers; it is caused by 
a deficiency of alpha-galactosidase A and accumulation of alpha-D-
galactosyl moieties, particularly globotriosylceramide accumulation 
(Gb3). These are found in Schwann cells and dorsal root ganglia 
together with deposits in central nervous system neurons and are 
likely causally related to the altered autonomic function and neuro-
pathic pain found in this disorder. 
 
Table 5. White Matter Lesion Quantification in Patients with Fabry Disease and in Controls  
Male Fabry patients Female Fabry patients Male controls Female controls 
WML classification n Age n Age n Age n Age 
No WML 4 26.8 (7.0) 7 30.7 (11.0) 9 34.1 (8.3) 7 34.1 (8.4) 
Mild WMLs 2 30.0 (4.0) 5 39.4 (9.6) 3 35.3 (17.1) 1 49.0 
Significant WMLs 4 48.5 (5.7) 3 46.0 (10.1) 0  0  
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 Other related abnormalities to be discussed are hypohidrosis 
and other abnormalities attributed to although usually in the normal 
range, compared to controls, nerve conduction parameters are sig-
nificantly impaired [38]. 
 The function of the peripheral nervous system is somewhat 
improved by ERT with reduction in neuropathic pain and an im-
provement of the detection threshold for cold and warm sensation 
in the hand and foot. Improvement in sweating and heat tolerance is 
 
 
 
 
 
 
 
 
 
 
 
 
Fig. (4). Voxel based comparison of mean diffusivity (MD) between patients with Fabry disease (FD), with (A) and without (B) significant white matter le-
sions (WMLs), and age matched controls. Significant MD elevations are projected on transverse sections (3 mm distance) of the fractional anisotropy tem-
plate. (A) MD values were significantly increased mainly in regions of the frontal, temporal, central and parietal white matter (p<0.001, uncorrected). In gray 
matter regions, significant MD increases were detected in the posterior thalamus bilaterally. (B) FD patients without significant WMLs (n = 18) showed sig-
nificant MD increases in similar locations but with a lower total cluster size. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Fig. (5). a) Pain and nerve fiber dysfunction in males with Fabry disease. Red area = course of pain. Green line = small nerve fiber dysfunction; with older age 
and more severe disease, nerve fiber dysfunction increases. b) Pain and nerve fiber dysfunction in females with Fabry disease. Red area = course of pain. 
Green line = small nerve fiber dysfunction; with older age and more severe disease, nerve fiber dysfunction increases. [From Marieke Biegstraaten et al. Small 
fiber neuropathy in Fabry disease. Molecular Genetics and Metabolism. June 2012]. 
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also noted following ERT. Despite those positive results conflicting 
findings exist about ERT role to normalize the function of the pe-
ripheral nervous system. Shiffmann et al. [39] reported the effect of 
a 3-year open-label extension of a previously reported 6-month 
placebo-controlled enzyme replacement therapy (ERT) trial in 
which 26 hemizygous patients with Fabry disease received 0.2 
mg/kg of alpha-galactosidase A every 2 weeks. The effect of ERT 
on neuropathic pain scores while off pain medications, quantitative 
sensory testing, quantitative sudomotor axon reflex test (QSART), 
and thermoregulatory sweat test (TST) is reported. In the patients 
who crossed-over from placebo to ERT (n = 10), mean pain-at-its-
worst scores on a 0-10 scale decreased (from 6.9 to 4.5). There was 
a significant reduction in the threshold for cold and warm sensation 
in the foot. At the 3-year time-point, pre-ERT sweat excretion in 17 
Fabry patients was 0.24 +/- 0.33 microl/mm(2) vs. 1.05 +/- 0.81 in 
concurrent controls (n = 38). Sweat function improved 24-72 h 
post-enzyme infusion (0.57 +/- 0.71 microl/mm(2) and normalized 
in four anhidrotic patients. TST confirmed the QSART results. 
Authors concluded that prolonged ERT in Fabry disease leads to a 
modest but significant improvement in the clinical manifestations 
of the small-fiber neuropathy associated with this disorder. QSART 
may be useful to further optimize the dose and frequency of ERT.  
 Severe neuropathic pain and hypohidrosis are important symp-
toms of Fabry disease, particularly in the first three decades of life. 
The pain is associated with a length-dependent small-fibre neuropa-
thy that also causes a selective deficiency of cold perception. Cold  
 
exposure often accentuates the pain and worsens thermal percep-
tion. The hypohidrosis leads to poor exercise and heat tolerance. 
The mechanisms by which alpha-galactosidase A deficiency causes 
these physiological abnormalities are poorly understood. The stored 
glycolipid (globotriaosylceramide) may interfere with the function 
of cellular membrane proteins, such as ion channels, or may lead to 
cytotoxicity (Fig. 6). The characteristic neuropathic pain can be 
symptomatically treated with various types of anticonvulsant drugs, 
such as carbamazepine. Improvement in neuropathic pain as a pri-
mary outcome measure has been useful in demonstrating that en-
zyme replacement therapy is effective in improving pain-related 
quality of life in Fabry disease. Overall, although these findings are 
encouraging, they do not suggest complete normalization of the 
peripheral nerve function. It is possible that early treatment before 
irreversible axonal loss, or higher and more frequent dosing may be 
more effective. Alternatively, as seen also in the Fabry vascular 
diathesis, perhaps the infused enzyme has insufficient access to 
affected sensory nerves and ganglia. This hypothesis is supported 
by the observation of poor storage clearance in non-vascular endo-
thelial cells in a patient who received 2.5 years of infusions of agal-
sidase beta. The dysfunction of the peripheral nervous system is 
easily assessable and more readily reversible with specific therapy 
than the destructive processes that occur in organs such as the kid-
ney. In future, therefore, it is likely that neuropathic pain, quantita-
tive sensory testing and hypohidrosis will serve as clinical outcome 
measures for studies of specific and effective therapies for Fabry 
disease. 
 
 
 
 
 
 
 
 
Fig. (6). Lamellated bodies (arrowhead) in the axons close to the vacuolated eccrine sweat gland (6000). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Fig. (7). Cerebral CT reveals malacic changes of periventrivular white matter, due to a probable chronic hypoxia and small hypodense areas that are compati-
ble with ischemic lesions, in a 55 year-old female patient with AFD. 
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CEREBROVASCULAR INVOLVEMENT IN ANDERSON-
FABRY DISEASE 
 Fabry disease pathogenesis consists of a glycosphingolipid 
storage in endothelial and smooth muscle cells ad neurons of the 
autonomic nervous system (Fig. 7). Anderson-Fabry disease clinical 
manistestations are essentially vascular (or miscrovascular) 
complications (such as cerebral disease), with a not well understood 
pathophysiology. Some studies indicate that vascular lesions of 
Anderson- Fabry disease may be related to endothelial dysfunction, 
alterations in cerebral perfusion and a pro-thrombotic state 
[40,20,41,42]. To date not well clear is the issue about the concept 
if a GB3 storage in the endothelial cells and the pro-thrombotic 
state is the origin of arterial damage or whether smooth muscle cell 
proliferation in the arterial media layer could represent the first step 
of Anderson-Fabry vascular pathology [43,44]. Furthermore a small 
fiber neuropathy could influence vascular reactivity as well whereas 
normal early atherogenesis have been described in patients with 
AFD and various grade of organ damage. Some studies showed a 
high intima media thickness of various arterial sites [44,45]. This 
finding has been also observed in a-galactosidase A deficient mouse 
model [46]. Although Moore et al. [47] did not confirm this finding 
in a group of 7 patients with AFD. 
 Other studies [48,49] showed that the blood flow is decreased 
[50] and vascular resistance is increased in patients with Fabry 
disease. Other authors reported a decreased coronary blood flow 
reserve [51,52]. Altarescu et al. showed reported an increased fore-
arm arterial blood flow after intra-arterial infusion of acetylcholine 
in Anderson- Fabry patients [53] (Fig. 8). So the authors concluded 
that in Fabry disease the abnormal vascular responses were endo-
thelium dependent.  
 In contrast, in the a-galactosidase A deficient mouse model, 
there was a reduced reactivity to acetylcholine [54]. Furthermore, 
authors showed increased activity of COX-1 and COX-2 in the 
same model [55]. Two clinical studies reported alterations in cere-
bral blood flow by transcranial ultrasonography [56,57, 58]. Never-
theless other studies reported enhanced blood flow, for example 
CBFV was increased in treated and untreated Fabry patients in a 
study by Moore et al. [59]. Studies reporting PET scanning finding 
confirmed this [60,61] (Fig. 9). 
 Affected brain area topography in Anderson Fabry disease on 
MRI, mainly shows that the posterior and periventricular white 
matter, were the areas affected by a relative hyperperfusion (Fig. 
10). 
 These findings could be due to a dysregulation of the nitric 
oxide pathway, leading to excessive protein nitration. White matter 
lesions (WMLs) are a typical finding in Fabry disease patients and 
they are related to microvascular ischemic lesions [62] and fre-
quently asymptomatic.  
 The histopathology of Fabry arteries shows, as the most impor-
tant and early finding, an involvement of the smooth muscle cell 
with stored glycolipid [63,64,65]. 
 Barbey et al. [65] reported that plasma of patients with AFD 
stimulate proliferation of vascular smooth muscle cells and cardio-
 
 
 
 
 
 
 
 
Fig. (8). Mean blood flow at baseline and after intra-arterial infusion of ACh (A) and change in mean blood flow after intra-arterial infusion of ACh and L-
NMMA (B). 
 
 
 
 
 
 
Fig. (9). A. Resting rCBF SPM{t} map of significantly increased blood flow in Fabry group (n=26) compared with control group (n=10) after template coreg-
istration of individual PET studies. Resting rCBF in control was not significantly greater than Fabry group at any set-level statistic, with no significantly cor-
rected clusters or voxels (data no shown). Increasing SPM{t} voxel value above threshold is shown by color bar. B. Resting rCBF SPM{t} map of signifi-
cantly decreased regional cerebral blood flow in ERT patient group (n=14) compared with placebo group (n=12) after template coregistration of individual 
PET studies. No significant decrease in rCBF occurred in placebo group compared with ERT group. Increasing SPM{t} voxel value above threshold is shown 
by color bar. 
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myocytes, whereas Brakch et al. showed that sphingosine-1-phos-
phate is growth-promoting factor active in subjects in Fabry disease 
[66]. Furthermore Aerts et al. showed that a new substance, the 
lyso-compound of globotriaosylceramide (Gb3), lyso Gb3 or lyso-
CTH able to induce smooth muscle cell proliferation in vitro [67] 
(Fig. 11). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Fig. (10). End organ damage associated with cerebral hyper-perfusion. A. 
Cerebral blood flow map of a single patient with Fabry disease using an 
MRI spin tagging technique. The image shows relative hyper-perfusion in 
the posterior circulation territory including the pulvinar region. B. T1-
weighted MRI image showing pulvinar hyperintensity. This abnormality is 
seen in about 30% of patients with the disease. C. Cerebral CT of the Fabry 
patient showing calcifications in the pulvinar, cerebral white matter and 
cerebellum. 
[From David F Moore et al. The cerebral vasculopathy of Fabry disease. 
Journal of the Neurological Sciences. June 2007] 
 
 The increase in IMT is probably a echographic finding more 
frequent among AFD alteration in vessel wall than the more tradi-
tional IMT changes observed in premature atherosclerotic disease. 
atheromatous plaque formation is rare in AFD and, when present, 
stenotic lesions have a different aspect with a more diffuse location. 
On this basis Fabry disease could represent a possible risk factor for 
widespread atherosclerosis in association with other risk factors, 
such as renal insufficiency, diabetes and hypertension.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
A 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
B 
Fig. (11). A Detection of lyso-Gb3 in plasma of Fabry patient. (Top) Struc-
ture of lyso-Gb3. (Middle and Bottom) Chromatograms obtained for pure 
lyso-Gb3 (Middle Left), normal plasma (Bottom Left), normal plasma 
spiked with lyso-Gb3 (Middle Right), and Fabry hemizygote plasma (Bot-
tom Right). B. Increased proliferation of smooth muscle cells by exposure 
to lyso-Gb3. Cells were exposed for 24 h to indicated concentrations of 
lyso-Gb3 (), lactosylsphingosine (), or Gb3 (). The incorporation of 
radioactive thymidine per well is depicted. 
 
 Cerebrovascular disease may progress asymptomatically in the 
early stages of Fabry disease (FD). A recent study [68] was con-
ducted with the aim to test whether functional transcranial Doppler 
(fTCD) could provide useful data in the evaluation of these pre-
symptomatic FD patients. A cohort of 12 adult FD patients from 
families with the classical phenotype of the disease was evaluated 
with fTCD in the posterior cerebral artery. Compared to healthy 
controls, resting blood velocities were significantly lower in the FD 
cohort (p = 0.032 for systolic, p = 0.021 for diastolic). fTCD sug-
gested a disturbed neurovascular coupling in the visual cortex of 
FD patients, with lower gain (p = 0.007) and rate time (p = 0.019). 
Men had a significantly higher attenuation (p = 0.013) and lower 
natural frequency (p = 0.046) than the heterozygous women. These 
data are the first to suggest that patients with FD may develop cor-
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tical vascular dysfunction in the territory of the posterior circula-
tion, early in the natural history of the disease. If the present find-
ings are confirmed in larger, prospective studies, fTCD will be 
useful for assessing stroke risk in as yet asymptomatic FD patients, 
improving preventive therapeutic management. 
 Another study by Uçeyler et al. [69] investigated cervical and 
cerebral blood flow characteristics in patients with Fabry disease at 
baseline and under enzyme replacement therapy. In this case-
control study authors prospectively studied 68 patients with Fabry 
disease with extracranial and transcranial Doppler sonography and 
they compared extracranial and transcranial cervical and cerebral 
blood flow properties in all patients with Fabry disease and in sub-
groups of those with or without enzyme replacement therapy, male 
and female, and with normal or impaired renal function. Eight male 
patients were investigated at baseline and 1 year after initiation of 
enzyme replacement therapy. This study shows that cervical and 
cerebral blood flow parameters in patients with Fabry disease are 
not different from normal values regardless of sex, renal function, 
or enzyme replacement therapy. Cervical and cerebral blood flow 
measured with extracranial and transcranial Doppler sonography is 
not altered in patients with Fabry disease.  
 A study [70] evaluated cerebral blood flow velocities and cere-
bral autoregulation in Anderson- Fabry subjects. Authors evaluat-
ede Resistance Index, Pulsatility Index, Cerebrovascular Resis-
tance, and and mean CBFV Pulsatility Index, Cerebrovascular Re-
sistance (P < 0.05), and the transfer function gain between low fre-
quency oscillations in mean blood pressure and mean CBFV were 
higher in patients than in controls. Authors showed that the de-
crease of CBFV may be due to stenoses of resistance vessels and 
dilatation of the insonated segment of the middle cerebral artery 
due to reduced sympathetic tone and vessel wall pathology with 
decreased elasticity. Both, reduced CBFV and impaired cerebral 
autoregulation, are candidate cerebrovascular risk factors in patients 
with Anderson-Fabry disease. 
WHITE MATTER LESIONS IN ANDERSON-FABRY DIS-
EASE 
 White matter lesions (WMLs), commonly seen as hyperintensi-
ties on T2-weighted MRI scans of healthy elderly individuals, are 
considered to be related to small vessel disease in the brain, and are 
often associated with subtle cognitive and functional impairments. 
WMLs also show a strong correlation with a wide range of neu-
rodegenerative and neuropsychiatric disorders. Although a number 
of vascular risk factors for WMLs have been identified, genetic 
factors are also important with twin and family studies reporting 
high heritability. Mutations in several genes have been described 
that lead to monogenic disorders manifesting WMLs, such as Fabry 
disease and CADASIL. Because most individuals with WMLs do 
not have Mendelian disorders, most of the focus has been on single 
nucleotide polymorphisms as genetic risk markers for WMLs, ei-
ther directly or through their interactions with other genes or medi-
cal risk factors. Candidate genes examined to date include those 
involved in cholesterol regulation and atherosclerosis, hypertension, 
neuronal repair, homocysteine levels, and oxidative stress path-
ways. In addition, although there have been a few genome-wide 
linkage studies, only one genome-wide association study has been 
performed. The majority of the genetic findings need independent 
replication, and studies need to be extended to other candidate 
genes. Collaborative efforts to examine genome-wide associations 
in large samples of both sexes of a broad age range using longitudi-
nal studies are necessary. The identification of individuals geneti-
cally at risk of developing white matter lesions will have important 
implications for recognizing the etiology of WMLs and thereby 
developing clinical intervention strategies for their prevention. 
Conventional MRI shows a progressive load of white matter lesions 
(WMLs) due to cerebral vasculopathy in the course of AFD. To 
quantify brain structural changes in clinically affected male and 
female patients with AFD, Fellgiebel A. et al. [71] performed a 
prospectiveDiffusion-Tensor Imaging (DTI) study in 27 adult Fabry 
patients (13m, 14f) and 21 age-matched controls (12 m, 9f). Global 
Mean Diffusivity (MD) was increased in FD (P = 0.003) whereas 
global Fractional Anisotropy (FA) did not differ significantly be-
tween FD and controls. Even FD patients without significant 
WMLs (9m, 9f) showed increased global MD (P = 0.004). Regions 
of interest with significant MD elevations were located in the fron-
tal, parietal and temporal white matter. No differences of thalamic 
and hippocampal DTI measurements could be detected between FD 
and controls. DTI parameters did not differ between male and fe-
male patients. The data provide the first evidence of a pattern of 
marked structural brain tissue alterations in adult FD male and fe-
male patients even without WMLs. DTI seems to be an appropriate 
diagnostic tool to quantify brain tissue integrity in FD. Moreover, 
this method could be favorable for longitudinal assessment of brain 
structure alterations in FD, and for monitoring the cerebral effects 
of enzyme replacement therapy. 
 Moore et al. [72] set to determine whether elevated resting CBF 
in Fabry disease is primarily a cerebrovascular abnormality or is 
secondary to enhanced neuronal metabolism. The relationship of 
cerebral metabolism and blood flow to Fabry leukoencephalopathy 
was also investigated.  
 Authors measured the global and regional cerebral metabolic 
rate of glucose using 18-fluoro-deoxyglucose (FDG) and PET in 16 
patients with Fabry disease (7 patients with leukoaraiotic lesions 
and 9 without) and in 7 control subjects. MRI fluid attenuated in-
version recovery (FLAIR) studies were also performed in the pa-
tient and control groups. All control subjects had normal MRI 
FLAIR studies with no high-signal deep white matter lesions 
(WML). Patients were partitioned into FLAIR lesion and non-
FLAIR lesion groups. Authors found no evidence of cerebral glu-
cose hypermetabolism in Fabry disease. On the contrary, signifi-
cantly decreased regional cerebral glucose metabolism (rCMRGlu) 
was found particularly in the deep white matter in the Fabry non-
lesion group and exacerbated in the lesion group. Lesion-
susceptible regions were relatively hyperperfused in non-lesion 
patients compared to the control group. They conclude that the 
elevated rCBF and decreased white matter rCMRGlu indicate a 
dissociation between metabolism and blood flow suggesting 
chronic deep white matter metabolic insufficiency. 
 Impaired kidney function is thought to be associated with small 
vessel disease, outcome, and mortality in the general stroke popula-
tion. Data are limited regarding young patients.  
 Steinicke R. et al. [73] conducted a study to investigate the 
association of kidney function and white matter hyperintensities 
(WMHs) in young patients with first ischemic stroke. Authors ana-
lyzed 2500 young (18-55 years) patients with first-ever ischemic 
stroke from the prospective observational Stroke in Young Fabry 
Patients (SIFAP1) study with available MRI data on WMH. Of 
these, 2009 had available data concerning estimated glomerular 
filtration rate (eGFR). Kidney function was expressed as eGFR by 
the Modification of Diet in Renal Disease method. Deep WMHs on 
MRI were classified by the Fazekas score. Multivariate analysis 
was performed using a regression model with random effects. Mean 
eGFR was 96.7 mL/min in those with WMH Grade 0 to 1 (none to 
mild), 90.7 mL/min in WMH Grade 2 (moderate), and 89 mL/min 
in WMH Grade 3 (severe). Univariate analysis revealed WMH to 
be associated with age (P<0.001), hypertension (P<0.001), cardio-
vascular disease (P=0.015), overweight (body mass index >25 
kg/m(2); P=0.013), current smoking (P=0.044), and eGFR 
(P=0.009). In multivariate analysis, age, hypertension, and eGFR 
remained associated with WMH severity. Authors concluded that in 
young patients with acute ischemic stroke, lower eGFR values in 
the normal range are associated with the presence of moderate to 
severe WMH. 
12    Current Pharmaceutical Design, 2013, Vol. 19, No. 00 Tuttolomondo et al. 
PSYCHIATRIC AND COGNITIVE DYSFUNCTION AND 
FUNCTIONAL INVOLVEMENT IN ANDERSON-FABRY 
DISEASE  
 Fabry disease affects multiple organ systems, including the 
central nervous system. A high proportion of patients with Fabry 
disease is at increased risk of developing neuropsychiatric symp-
toms, such as depression and neuropsychological deficits. Due to 
both somatic and psychological impairment, health-related quality 
of life (QoL) is considerably reduced in patients with Fabry disease. 
Although the pathophysiological mechanisms of Fabry disease have 
not been fully elucidated, it is surmised that sphingolipid deposits in 
the endothelium of small cerebral vessels lead to regional cerebral 
ischaemia, which may be accompanied by neuropsychiatric symp-
toms. Furthermore, patients with Fabry disease are chronically dis-
tressed by pain attacks and additional somatic and psychosocial 
impairment. The available literature on psychiatric and neuropsy-
chological findings, psychosocial adjustment and QoL during the 
natural course of Fabry disease in adults is reviewed in this chapter. 
Psychiatric symptoms, particularly depression, are highly prevalent 
in men and women with Fabry disease. Although more reliable data 
on neuropsychological deficits in the course of Fabry disease are 
needed, compelling evidence is available that almost all compo-
nents of QoL are impaired in affected patients. As neuropsychiatric 
symptoms and poor psychosocial adjustment seem to contribute to 
the low QoL of patients with Fabry disease, early therapeutic inter-
vention and prevention programmes, starting in childhood or ado-
lescence, are strongly recommended. 
 Literature on the neuropsychiatric and psychosocial aspects of 
Fabry disease reveals a paucity of reliable data. According to the 
available literature, depressive symptoms and disorders seem to 
occur frequently in males and females with Fabry disease. Depres-
sion is related to a high risk of suicide and elevated mortality, im-
paired psychosocial function and reduced QoL. This is consistent 
with other reports of depression occurring in the context of somatic 
illness, in which 20–50% of patients are found to suffer depressive 
episodes – for example, after myocardial infarction, stroke, cancer 
and diabetes mellitus [74,75,76]. From these studies, we have 
learned that co-morbid untreated depression might reduce both the 
prognosis of the somatic illness and the patient's QoL. 
 In a preliminary analysis of an ongoing study (MJ Müller and 
KM Müller, unpublished data), a high proportion of acutely de-
pressed individuals (55%) was found in a sample of 36 patients 
with Fabry disease, corroborating earlier observations. Addition-
ally, about one-third of male and more than two-thirds of female 
patients with Fabry disease had a lifetime diagnosis of major de-
pression according to internationally established diagnostic criteria 
(Diagnostic and Statistical Manual of Mental Disorders – Fourth 
Edition, DSM-IV). In addition, a case series has been published on 
four female heterozygotes with Fabry disease who had severe de-
pression [77].  
 Some authors [78] investigated neuropsychological and psychi-
atric function in AFD patients. They studied 16 AFD patients, aged 
7 to 61 years. Intelligence, language, vision-spatial abilities, mem-
ory, sensorimotor abilities, and attention and executive functions 
were tested with a computerized test battery as well as standard 
paper and pencil tests. The results were compared to known age-
based norms. In addition, all patients were screened for lifelong 
DSM-IV Axis-I and Axis-II psychiatric diagnoses, and 4 were in-
terviewed by a psychiatrist. Performance on most cognitive meas-
ures was within average range. All measures of information proc-
essing speed were significantly reduced, as were some measures of 
executive functions. Ten out of 16 patients met DSM-IV criteria for 
Axis I or Axis II diagnoses at some point in their lives. This pre-
liminary study delineates a psychiatric and cognitive phenotype in 
AFD patients and contributes to the growing field of characterizing 
behavioral phenotypes of patients with genetic diseases. Authors 
suggest that psychiatric and neuro-psychological evaluation could 
be included in the patient's evaluation. 
PULVINAR SIGN  
 Fabry disease is a multisystem X-linked disorder characterized 
clinically by angiokeratoma, corneal and lenticular abnormalities, 
acroparesthesia, renal and cardiac dysfunction and stroke. We 
sought to describe novel neuroimaging characteristics of Fabry 
disease. Moore et al. [79] reviewed neuroradiologic records of 104 
hemizygous patients with Fabry disease evaluated between 1994 
and 2002. In total, 94 MR studies consisting of T1- and T2-
weighted images were examined for the presence of hyperintensity 
on the T1-weighted images. Additional CT, gradient-echo (T2*-
weighted), and fat-suppression MR studies were reviewed to char-
acterize further the T1 abnormality in selected patients. In some 
patients, cerebral blood flow (CBF) was quantified by using arterial 
spin tagging (AST). Overall, 22 patients (approximately 23%) 
demonstrated pulvinar hyperintensity on T1-weighted images; the 
frequency increased with age to over 30% by age 50 years. Suscep-
tibility-weighted T2* studies demonstrated a low-signal-intensity 
abnormality in the pulvinar in the more severe cases, whereas CT 
demonstrated the pulvinar to be mineralized. CT attenuation corre-
sponded with an increasing signal intensity on T1-weighted images. 
Posterior circulation CBF was found to be elevated on individual 
AST studies, especially in the thalamus. Hyperintensity in the pulv-
inar on T1-weighted images is a common finding in Fabry disease, 
likely reflecting the presence of calcification. Although other min-
eralizing abnormalities may result in calcification of deep gray 
nuclei, exclusive involvement of the pulvinar may be distinctively 
characteristic to Fabry disease. Increased CBF in the posterior cir-
culation, particularly the thalamus, suggests that the dystrophic 
calcification is secondary to cerebral hyperperfusion and selective 
vulnerability of the pulvinar and adjacent thalamic nuclei. The find-
ing of isolated pulvinar hyperintensity on T1-weighted images 
should suggest Fabry disease, particularly when seen in conjunction 
with other nonspecific neuroradiologic manifestations of the disease 
(Figs. 12, 13,14). 
 Neuroradiological findings of AFD include ischemic stroke, 
white matter lesions, vascular abnormalities (vertebrobasilar doli-
choectasia and vessel tortuosity), and posterior thalamus involve-
ment (the so called pulvinar sign). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Fig. (12). Serial, axial T1-weighted MR images (5-mm sections) demon-
strate the range of pulvinar hyperintensities observed. 
A and B, Mild to moderate abnormality. C, Marked abnormality.  
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Fig. (13). Direct axial AST images demonstrateincreased relative CBF in 
the thalamus and posterior circulation at the anterior and posterior commis-
sure plane in a patient without (A) and one with (B) the T1-weighted MR 
imaging abnormality. The dark thalamic regions in the pulvinar in B corre-
spond to the damaged mineralized areas in the midst of the still hyperper-
fused pulvinar region. 
 
 A recent study [80] investigated the presence of the increased 
pulvinar signal intensity on T1-weighted imaging - pulvinar sign 
and its relationship with other clinical findings, in a non-selected 
cohort of Fabry patients. Authors performed a prospective analysis 
of two populations of patients (36 subjects) with Fabry disease. 
Patients were followed-up at the Department of Internal Medicine 
of the Bichat Hospital in Paris (France) and at the Neurological 
Clinic of the University Hospital of Padova (Italy). Brain MR stud-
ies of each patient included T1- and T2- weighted images, FLAIR 
sequences, and in some cases diffusion weighted images. A total of 
36 patients (16 males, 20 females) were investigated in 14 families. 
The pulvinar sign was found in 5 male patients, but not in female 
patients. Seven patients have had at least one stroke (territorial or 
lacunar). There was no correlation between stroke and the pulvinar 
sign. All patients with the pulvinar sign had hypertrophic cardio-
myopathy. Four patients out of five with the pulvinar sign were on  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Fig. (14). A. A FLAIR MRI image of a Fabry patient with a stroke in the 
right middle cerebral artery territory, possibly embolic in origin. B. MR 
angiography (MRA) showing mild to moderate dolichoectasia of the basilar 
artery in a patient with Fabry disease. C. Another patient with normal ap-
pearing cerebral blood vessels on MRA. D. A FLAIR image of the patient in 
2B showing a cross section of the dolichoectatic basilar artery. [From david 
f. moore et al. The cerebral vasculopathy of Fabry disease. Journal of the 
Neurological Sciences. June 2007] 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Fig. (15). Progression of clinical findings in Fabry's disease with age. Progression of any of the paths depicted can proceed independently from the others, 
which means that for some patients, cardiac disease will be the most severe whereas for others renal or CNS disease can predominate. LVH=left ventricular 
hypertrophy. TIA=transient ischaemic stroke. 
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dialysis or had a kidney transplantation. Findings of this study sug-
gest that the pulvinar sign is a highly specific sign of Fabry disease, 
found in male patients with cardiac signs and severe kidney in-
volvement. 
CONCLUSIONS  
 Fabry's disease is a rare hereditary lysosomal storage disease 
with multiorgan involvement. Deficiency of -galactosidase A ac-
tivity leads to accumulation of neutral glycosphingolipids, espe-
cially in vascular endothelial and smooth-muscle cells (Fig. 15). 
Along with progressive renal and cardiac dysfunction, stroke is a 
major and often life-threatening burden of the disease. Cerebral 
vasculopathy, confirmed by neuropathological, neuroradiological, 
and functional studies occurs commonly and leads to ischaemic 
cerebrovascular events at an early age. 
 
 
 
 
 
 
 
 
 
 
Fig. (16). Genealogic tree of patients with recurrent strokes. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Fig. (17). 
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 However, research has shown a high prevalence of ischaemic 
stroke and transient ischaemic attacks, along with imaging evidence 
of CNS involvement, in female patients with the disease, which 
suggests that at least in a subgroup of clinically affected women the 
severity of CNS disease is comparable to that in men. Recent stud-
ies have shown a high prevalence of the disease in young patients 
of both sexes with cryptogenic stroke, emphasising the need for 
more clinical attention to be paid to this under-diagnosed disease. 
 We [80] recently reported a case of a 56-year-old woman with 
recurrent cryptogenic strokes and a familiar history of acute cere-
brovascular disease (Fig. 16). Ophthalmological examination re-
vealed whorled opacities of the cornea (cornea verticillata) and 
dilated tortuous conjunctival vessels. She did not show other typical 
signs of Fabry disease such as acroparesthesias and angiokeratoma. 
The patient's alpha-galactosidase A activity was 4.13nmol/mL/h in 
whole blood. Alpha-galactosidase A gene sequence analysis (Fig. 
17) revealed a heterozygous single nucleotide point mutation at 
nucleotide c.550T>A in exon 4 in this woman, leading to the 
p.Tyr184Asn amino acid substitution.  
 Ischemic stroke is related to inflammation [82,83,84,85] and 
arterial stiffness [86,87] and no study had addressed this relation-
ship in patients with AF disease and cerebrovascular disease, so this 
topic could represent a possible future research line.  
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